Yamanouchi Vaprisol “Approvable” Letter Requests Additional Safety Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Discussions with FDA are ongoing but there is no timeframe for submission of a complete response, Yamanouchi says. Conivaptan would be first hyponatremia drug.